Table I.
Clinical features of the patients and tumor location.
| Oral cavity | Pharynx | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Overall | Tongue | FOM | BM | Gingiva | Overall | Meso | Hypo | Larynx | P-value | |
| Age | ||||||||||
| 45> | 6 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0.021 (OC vs. P) |
| 45< | 41 | 28 | 6 | 4 | 3 | 39 | 14 | 25 | 33 | |
| Gender | ||||||||||
| Female | 14 | 9 | 0 | 4 | 1 | 2 | 0 | 1 | 1 | 0.0034 (OC vs. P) |
| Male | 33 | 25 | 6 | 0 | 2 | 37 | 14 | 24 | 34 | 0.0018 (OC vs. L) |
| Tumor sizea,b | ||||||||||
| T1 | 8 | 6 | 2 | 0 | 0 | 1 | 0 | 1 | 8 | NS |
| T2 | 20 | 14 | 3 | 2 | 1 | 19 | 4 | 15 | 14 | |
| T3 | 13 | 10 | 1 | 2 | 0 | 9 | 6 | 3 | 6 | |
| T4 | 3 | 1 | 0 | 0 | 2 | 9 | 4 | 5 | 6 | |
| Lymph node involvementa | N0 vs. others | |||||||||
| N0 | 28 | 20 | 4 | 2 | 2 | 10 | 2 | 8 | 29 | 0.0016 (OC vs. P) |
| N1 | 8 | 6 | 1 | 1 | 0 | 7 | 3 | 4 | 1 | <0.0001 (P vs. L) |
| N2 | 10 | 7 | 1 | 1 | 1 | 20 | 9 | 11 | 4 | |
| N3 | 1 | 1 | 0 | 0 | 0 | 2 | 0 | 2 | 1 | |
| Stagea | I and II vs. III and IV | |||||||||
| I | 8 | 7 | 1 | 0 | 0 | 1 | 0 | 1 | 7 | 0.0004 (OC vs. P) |
| II | 17 | 12 | 3 | 1 | 1 | 5 | 0 | 5 | 11 | 0.0009 (P vs. L) |
| III | 10 | 7 | 1 | 2 | 0 | 9 | 4 | 5 | 6 | |
| IV | 12 | 8 | 1 | 1 | 2 | 24 | 10 | 14 | 11 | |
| Total | 47 | 34 | 6 | 4 | 3 | 39 | 14 | 25 | 35 | |
Patients who had recurrent lymph node metastasis were omitted from this classification. Meso, mesopharyngeal; Hypo, hypopharyngeal; NS, not significant. FOM, floor of mouth; BM, buccal mucosa; OC, oral cavity; P, pharynx; L, larynx.